JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Vertex Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

384.21 2.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

374.06

Max

383.83

Chiffres clés

By Trading Economics

Revenu

-267M

646M

Ventes

-142M

2.8B

P/E

Moyenne du Secteur

30.42

34.393

BPA

4.06

Marge bénéficiaire

23.33

Employés

6,100

EBITDA

-404M

782M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+34.17% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5B

121B

Ouverture précédente

381.78

Clôture précédente

384.21

Sentiment de l'Actualité

By Acuity

43%

57%

145 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 août 2025, 00:05 UTC

Actions en Tendance

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 août 2025, 21:21 UTC

Résultats
Principaux Mouvements du Marché

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 août 2025, 20:45 UTC

Résultats

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

5 mai 2025, 21:00 UTC

Résultats

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

5 août 2025, 20:44 UTC

Résultats

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 août 2025, 18:17 UTC

Résultats

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 août 2025, 15:25 UTC

Résultats

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 août 2025, 14:12 UTC

Résultats

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 août 2025, 11:27 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:55 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:36 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:18 UTC

Résultats

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

4 août 2025, 20:15 UTC

Résultats

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 août 2025, 20:14 UTC

Résultats

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 août 2025, 20:14 UTC

Résultats

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 août 2025, 20:14 UTC

Résultats

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 août 2025, 20:13 UTC

Résultats

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 août 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 août 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 août 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 août 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

6 mai 2025, 16:31 UTC

Résultats

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 mai 2025, 20:03 UTC

Résultats

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 mai 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 mai 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 mai 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 mai 2025, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 avr. 2025, 11:00 UTC

Actualités

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 avr. 2025, 09:30 UTC

Actualités

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Comparaison

Variation de prix

Vertex Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

34.17% hausse

Prévisions sur 12 Mois

Moyen 491.78 USD  34.17%

Haut 624 USD

Bas 405 USD

Basé sur 27 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

27 ratings

16

Achat

11

Maintien

0

Vente

Score Technique

By Trading Central

428.545 / 498.65Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

145 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.